Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Kanagawa Cancer Center · Kanagawa Prefectural Hospital Organization · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
633
total citations
- FWCI
- 67.85
- Percentile
- 100%
- References
- 35
Citations per year
Authors
25Topics & keywords
Topics
Keywords
- Medicine
- Erlotinib
- Internal medicine
- Bevacizumab
- Interim analysis
- Oncology
- Clinical endpoint
- Lung cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.